Evidence map›Paper›PMID 37565527›Full record

ArticleBiotechnology and bioengineering2024

Continuous precipitation-filtration process for initial capture of a monoclonal antibody product using a four-stage countercurrent hollow fiber membrane washing step.

Mirko Minervini, Matthew Mergy, Yuncan Zhu, Mario A Gutierrez Diaz, Craig Pointer, Oleg Shinkazh, Sheldon F Oppenheim, Steven M Cramer, Todd M Przybycien, Andrew L Zydney

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mirko MinerviniDepartment of Chemical Engineering, The Pennsylvania State University, State College, Pennsylvania, USA.
Matthew MergyDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
Yuncan ZhuDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
Mario A Gutierrez DiazDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
Craig PointerChromaTan, Inc., Gwynedd, Pennsylvania, USA.
Oleg ShinkazhChromaTan, Inc., Gwynedd, Pennsylvania, USA.
Sheldon F OppenheimTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Steven M CramerDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.ORCID http://orcid.org/0000-0003-4635-5221
Todd M PrzybycienDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.ORCID http://orcid.org/0000-0003-0111-3640
Andrew L ZydneyDepartment of Chemical Engineering, The Pennsylvania State University, State College, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-1865-9156
Rensselaer Polytechnic Institute · USChromaTan · USPennsylvania State University · USTakeda (United States) · US

Funding

Biomolecular Science and Engineering Training Program at Rensselaer Polytechnic InstituteT32GM141865 · NIGMS · RENSSELAER POLYTECHNIC INSTITUTE · PI Blanca Barquera, JUERGEN HAHN · 2021 to 2026
$2.5M
CESMIINational Institute for Innovation in Manufacturing BiopharmaceuticalsNational Institute of General Medical Sciences (NIGMS) Biomolecular Science and Engineering Training Program T32GM141865NIGMS NIH HHS T32 GM141865U.S. Department of Commerce, National Institute of Standards and Technology 70NANB17H002U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE) under the Clean Energy Smart Manufacturing Innovation Institute (CESMII) 4550GZA025U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE) under the Clean Energy Smart Manufacturing Innovation Institute (CESMII) de-ee0007613
6 · The paper itself

Abstract

The significant increase in product titers, coupled with the growing focus on continuous bioprocessing, has renewed interest in using precipitation as a low-cost alternative to Protein A chromatography for the primary capture of monoclonal antibody (mAb) products. In this work, a commercially relevant mAb was purified from clarified cell culture fluid using a tubular flow precipitation reactor with dewatering and washing provided by tangential flow microfiltration. The particle morphology was evaluated using an inline high-resolution optical probe, providing quantitative data on the particle size distribution throughout the precipitation process. Data were obtained in both a lab-built 2-stage countercurrent washing system and a commercial countercurrent contacting skid that provided 4 stages of continuous washing. The processes were operated continuously for 2 h with overall mAb yield of 92 ± 3% and DNA removal of nearly 3 logs in the 4-stage system. The high DNA clearance was achieved by selective redissolution of the mAb using a low pH acetate buffer. Host cell protein clearance was 0.59 ± 0.08 logs, comparable to that based on model predictions. The process mass intensity was slightly better than typical Protein A processes and could be significantly improved by preconcentration of the antibody feed material.

Indexed as

Antibodies, MonoclonalCricetulusAnimalsChemical PrecipitationCHO CellsCountercurrent DistributionFiltrationAntibodies, MonoclonalmAbmonoclonal antibodyprecipitationprimary capturetangential flow filtration

Identifiers

PMID37565527
PMCPMC10858288
OpenAlexW4385724741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.